-
公开(公告)号：US10744214B2
公开(公告)日：2020-08-18
申请号：US16065393
申请日：2016-12-28
Applicant: STC.UNM
Inventor： Jeffrey P. Norenberg
Abstract: The present invention is directed to novel non-invasive diagnostic took to dispose numerous disease states and/or conditions. The presets invention, represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. The methods described herein are able to diagnose, treat and/or monitor the therapy of numerous diseases and conditions including atherosclerosis, atherothrombosis, cerebral vascular disease, cerebral ischemia, cerebral infarct and meningitis as well as pneumonitis, pericarditis, multiple sclerosis, lupus erythematosus and pancreatitis, among others.
-
公开(公告)号：US20190192700A1
公开(公告)日：2019-06-27
申请号：US16181904
申请日：2018-11-06
Applicant: STC.UNM
Inventor： Jeffrey P. Norenberg
IPC: A61K51/08 , A61K45/06 , A61K31/7068 , A61K38/31
CPC classification number: A61K51/08 , A61K31/7068 , A61K38/31 , A61K45/06 , A61K51/083 , A61K51/088 , A61K2300/00
Abstract: A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.
-
3.发明申请NON-INVASIVE DIAGNOSTIC AGENTS AND METHODS OF DIAGNOSING INFECTIOUS DISEASE 审中-公开非侵入性诊断试剂和诊断感染性疾病的方法公开(公告)号：US20160287728A1
公开(公告)日：2016-10-06
申请号：US15153411
申请日：2016-05-12
Applicant: STC.UNM
Inventor： Jeffrey P. Norenberg
IPC: A61K51/04
CPC classification number: A61K51/0453 , A61K31/4178 , A61K51/00 , A61K51/044 , A61K51/0497 , G01N33/569 , G01N2333/70525 , G01N2333/70553 , Y02A50/47 , Y02A50/481
Abstract: The present invention is directed to novel non-invasive diagnostic tools to diagnose numerous infectious disease states or conditions. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to therapeutic treatments and other interventions or therapies used in the treatment of these disease states or conditions. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. Pharmaceutical compositions are also described.
Abstract translation: 本发明涉及用于诊断许多传染病状态或病症的新型非侵入性诊断工具。 本发明代表了本领域的显着进步，其目前依赖于组织活检以诊断这些疾病状态。 该新型成像探针能够检测感染的细胞以及组织。 这代表了使用非侵入性分子成像技术在NHL的诊断和分期中向前推进的量子进程。 这种新型探针也可用于监测患者对治疗这些疾病状态或病症治疗中使用的治疗性治疗和其他干预措施或疗法的反应。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。 还描述了药物组合物。
-
4.发明申请Non-Invasive Diagnostic Agents of Cancer and Methods of Diagnosing Cancer, Especially Leukemia and Lymphoma 有权癌症的非侵入性诊断剂和诊断癌症，特别是白血病和淋巴瘤的方法公开(公告)号：US20130216478A1
公开(公告)日：2013-08-22
申请号：US13854560
申请日：2013-04-01
Applicant: STC.UNM
Inventor： Jeffrey P. Norenberg , Richard S. Larson
CPC classification number: C07F5/003 , A61K47/22 , A61K49/106 , A61K51/0474 , A61K51/0482 , A61K51/0485 , A61K51/0497 , C07F9/94
Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
Abstract translation: 本发明涉及用于对癌症特别是白血病和非霍奇金淋巴瘤（NHL）进行成像的新型非侵入性诊断工具，其体内毒性最小。 本发明代表了目前依赖于组织活检以诊断这些癌症的本领域的明显进步。 该新型成像探针能够检测癌前细胞，以及它们在组织中的转移扩散。 这代表了使用非侵入性分子成像技术在NHL的诊断和分期中向前推进的量子进程。 该新型探针也可用于监测患者对化疗治疗的反应和用于治疗NHL的其他干预措施或疗法。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。
-
公开(公告)号：US10548994B1
公开(公告)日：2020-02-04
申请号：US14196343
申请日：2014-03-04
Applicant: STC.UNM
Inventor： Erin Damita Milligan , Jeffrey P. Norenberg
IPC: A61K31/4166 , A61K51/04 , A61K31/4174 , A61K38/18 , A61K38/20 , A61K38/34
Abstract: In one embodiment, the invention provides a method of treating a subject suffering from chronic neuropathic pain and/or allodynia by administering a therapeutically-effective amount of at least one LFA1 antagonist to the subject. In a preferred embodiment, the invention provides a method of treating a subject suffering from chronic neuropathic pain and/or allodynia, the method comprising administering intrathecally to the subject a therapeutically-effective amount of microparticles comprising PLGA-encapsulated pDNA-IL-10, optionally in combination with a therapeutically-effective amount of intrathecally-administered CpG oligodeoxynucleotide (CpG ODN) and/or at least one LFA1 antagonist.
-
Patent Agency Ranking
公开(公告)号：US20160303258A1
公开(公告)日：2016-10-20
申请号：US15100883
申请日：2014-12-03
Applicant: MILLENNIUM PHARMACEUTICALS, INC. , INVICRO LLC , UNIVERSITY OF IOWA RESEARCH FOUNDATION , STC.UNM
Inventor： Donna Cvet , Swapnil Raut , Michael K. Schultz , Jeffrey P. Norenberg , Tamara Anderson Daniels , John William Hoppin
CPC classification number: A61K51/0482 , A61K38/50 , A61K45/06 , A61K51/08 , A61K51/1063 , C07K7/08 , C07K16/3046 , C07K16/40 , C12N9/88 , C12Y305/01001 , C12Y406/01002 , G01N33/5011 , G01N33/60 , Y02A50/473 , A61K2300/00
Abstract: This disclosure provides radiolabeled compounds that bind to guanylyl cyclase C (GCC) and which can bind cancer cells that express GCC. Exemplary compounds comprise a chelating moiety capable of binding a radioactive atom, a peptide capable of binding GCC, and a linker moiety connecting the two. This disclosure also provides methods of detecting and treating cancer using the compounds described herein.
Abstract translation: 本公开提供了结合鸟苷酸环化酶C（GCC）并且可以结合表达GCC的癌细胞的放射性标记的化合物。 示例性化合物包括能够结合放射性原子的螯合部分，能够结合GCC的肽和连接两者的连接体部分。 本公开还提供了使用本文所述的化合物检测和治疗癌症的方法。
-
7.发明授权Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma 有权癌症的非侵入性诊断剂和诊断癌症的方法，特别是白血病和淋巴瘤公开(公告)号：US08834838B2
公开(公告)日：2014-09-16
申请号：US13854560
申请日：2013-04-01
Applicant: STC.UNM
Inventor： Jeffrey P. Norenberg , Richard S. Larson
CPC classification number: C07F5/003 , A61K47/22 , A61K49/106 , A61K51/0474 , A61K51/0482 , A61K51/0485 , A61K51/0497 , C07F9/94
Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
Abstract translation: 本发明涉及用于对癌症特别是白血病和非霍奇金淋巴瘤（NHL）进行成像的新型非侵入性诊断工具，其体内毒性最小。 本发明代表了目前依赖于组织活检以诊断这些癌症的本领域的明显进步。 该新型成像探针能够检测癌前细胞，以及它们在组织中的转移扩散。 这代表了使用非侵入性分子成像技术在NHL的诊断和分期中向前推进的量子进程。 该新型探针也可用于监测患者对化疗治疗的反应和用于治疗NHL的其他干预措施或疗法。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。
-
公开(公告)号：US09610371B2
公开(公告)日：2017-04-04
申请号：US14669313
申请日：2015-03-26
Applicant: STC.UNM
Inventor： Jeffrey P. Norenberg
CPC classification number: A61K51/08 , A61K31/7068 , A61K38/31 , A61K45/06 , A61K51/083 , A61K51/088 , A61K2300/00
Abstract: A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.
-
9.发明授权Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma 有权癌症的非侵入性诊断剂和诊断癌症的方法，特别是白血病和淋巴瘤公开(公告)号：US09546186B2
公开(公告)日：2017-01-17
申请号：US14451916
申请日：2014-08-05
Applicant: STC.UNM
Inventor： Jeffrey P. Norenberg , Richard S. Larson
CPC classification number: C07F5/003 , A61K47/22 , A61K49/106 , A61K51/0474 , A61K51/0482 , A61K51/0485 , A61K51/0497 , C07F9/94
Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
Abstract translation: 本发明涉及用于对癌症特别是白血病和非霍奇金淋巴瘤（NHL）进行成像的新型非侵入性诊断工具，其体内毒性最小。 本发明代表了目前依赖于组织活检以诊断这些癌症的本领域的明显进步。 该新型成像探针能够检测癌前细胞，以及它们在组织中的转移扩散。 这代表了使用非侵入性分子成像技术在NHL的诊断和分期中向前推进的量子进程。 该新型探针也可用于监测患者对化疗治疗的反应和用于治疗NHL的其他干预措施或疗法。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。
-
公开(公告)号：US20150196673A1
公开(公告)日：2015-07-16
申请号：US14669313
申请日：2015-03-26
Applicant: STC.UNM
Inventor： Jeffrey P. Norenberg
IPC: A61K51/08 , A61K31/7068 , A61K45/06
CPC classification number: A61K51/08 , A61K31/7068 , A61K38/31 , A61K45/06 , A61K51/083 , A61K51/088 , A61K2300/00
Abstract: A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.
Abstract translation: 通过施用增加生长抑素受体表达的试剂和细胞毒性识别配体来治疗患有癌症或癌前病症的受试者。 在替代实施方案中，放射性标记的生长抑素类似物用于治疗癌症或癌前病症。
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.038 seconds)
